Chemomab Therapeutics Ltd.
CMMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534248
In the last 90 days, Chemomab Therapeutics Ltd. insiders filed 0 open-market purchases and 1 sale; 13 institutions reported holding it in 13F filings for Q2 2026, worth $615.3K in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:27 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 10-K | 10-K |
| Reported | – | – | – | Feb 21, 2023 | Mar 9, 2022 |
| Cost of revenue | $2.33M | $2.46M | $4.39M | – | – |
| Operating expenses | $9.57M | $14.7M | $25.5M | $28.5M | $12.4M |
| Research and development | $5.83M | $11.3M | $18.4M | $17.0M | $6.33M |
| Selling, general and administrative | $3.73M | $3.41M | $7.08M | $11.6M | $6.03M |
| Operating income | -$112.0M | -$103.0M | – | – | – |
| Income tax | $0 | $0 | $0 | -$534.0K | – |
| Net income | -$8.99M | -$13.9M | -$24.2M | -$27.6M | -$12.5M |
| EPS, basic | $0.018 | $0.039 | $0.103 | $0.121 | – |
| EPS, diluted | $0.018 | $0.039 | $0.103 | $0.121 | – |
| Weighted shares, basic | 510.2M | 359.0M | 235.0M | 227.6M | – |
| Weighted shares, diluted | 510.2M | 359.0M | 235.0M | 227.6M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 10-K | 10-K |
| Reported | – | – | – | Feb 21, 2023 | Mar 9, 2022 |
| Cash and equivalents | $7.56M | $6.07M | $9.29M | $13.5M | $15.2M |
| Total current assets | $13.4M | $16.0M | $20.9M | $41.7M | $62.7M |
| Property, plant and equipment | $176.0K | $250.0K | $303.0K | $367.0K | $357.0K |
| Total assets | $13.8M | $17.0M | $22.2M | $43.1M | $64.4M |
| Total current liabilities | $1.48M | $3.22M | $4.84M | $6.75M | $2.65M |
| Total liabilities | $1.48M | $3.43M | $5.15M | $6.84M | $2.89M |
| Shareholders' equity | $12.3M | $13.5M | $17.0M | $36.2M | $61.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 10-K | 10-K |
| Reported | – | – | – | Feb 21, 2023 | Mar 9, 2022 |
| Operating cash flow | -$11.1M | -$15.4M | -$23.6M | -$20.4M | -$12.4M |
| Capital expenditures | $3.00K | $0 | $3.00K | $68.0K | $239.0K |
| Free cash flow | -$11.1M | -$15.4M | -$23.6M | -$20.4M | -$12.6M |
| Stock-based compensation | $623.0K | $617.0K | $1.49M | $3.21M | $2.02M |
| Investing cash flow | $5.39M | $2.30M | $15.9M | $19.5M | -$45.2M |
| Financing cash flow | $7.16M | $9.87M | $3.50M | -$808.0K | $61.1M |
| Net change in cash | $1.42M | -$3.22M | -$4.23M | -$1.65M | $3.51M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Dec 31, 2025 | 575.4M | +52.6% | SEC |
| Dec 31, 2024 | 377.1M | +32.7% | SEC |
| Dec 31, 2023 | 284.1M | +28.6% | SEC |
| May 8, 2023 | 11.0M | −3.1% | SEC |
| Dec 31, 2022 | 221.0M | +1,838.4% | SEC |
| Nov 8, 2022 | 11.5M | +1.1% | SEC |
| Aug 11, 2022 | 11.4M | +0.3% | SEC |
| May 11, 2022 | 11.4M | −69.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-4 in Q3 2025.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.